-
Someone is manipulating jumping it to 27 when offers at 23, 24, 25! I'm not offering anymore!
-
Finally got my offer: Really pleased to be into this (at right price) even if it takes a while to become a serious stock. Now I'm a holder intend sharing biz ideas with them direct! (but as mentioned, think they have someone good on-board in the marketing game) Next sales reports will be the tell-all. If what I'm picking this stock could go amongst the best;-)
-
Good news for Promisia, still a penny stock but maybe not such a 'penny dreadful' now. Another loss but nearly a million in sales, and apart from NZ target markets are barely touched yet. It was mentioned at the recent ASM that sales revenue in NZ exceeds the advertising spend. I see a lot of TV and internet advertising.
Sounds like Arthrem for dogs is well on the way, with the palatibility issue apparently sorted. Could be a lucrative global market as it is a natural product, and cheaper than a visit to the vet plus prescription.
And a hint of another product with a clinical trial begun.
-
Originally Posted by artemis
Good news for Promisia, still a penny stock but maybe not such a 'penny dreadful' now. Another loss but nearly a million in sales, and apart from NZ target markets are barely touched yet. It was mentioned at the recent ASM that sales revenue in NZ exceeds the advertising spend. I see a lot of TV and internet advertising.
Sounds like Arthrem for dogs is well on the way, with the palatibility issue apparently sorted. Could be a lucrative global market as it is a natural product, and cheaper than a visit to the vet plus prescription.
And a hint of another product with a clinical trial begun.
someone just made me 28% better off today LOL. Already thinking to increase my holding. Cripes, if they go to a dollar next couple years I could retire! ...ride my MT-bike more! ;-) A million sales is poor really: It's the turn-over barely good enough for a one-man-band. We'll know they're worth something when they get to TEN mill in sales which they need to get to pronto to stretch out time that they'll get "run over" by competitors! IMHO.
Last edited by jim9358; 30-08-2016 at 01:07 PM.
-
Originally Posted by jim9358
someone just made me 28% better off today LOL. Already thinking to increase my holding. Cripes, if they go to a dollar next couple years I could retire! ...ride my MT-bike more! ;-) A million sales is poor really: It's the turn-over barely good enough for a one-man-band. We'll know they're worth something when they get to TEN mill in sales which they need to get to pronto to stretch out time that they'll get "run over" by competitors! IMHO.
Well done holders.....I sense the beginnings of another BLT here!
-
Originally Posted by Left field
Well done holders.....I sense the beginnings of another BLT here!
sure hope not! (tongue-n-cheek right?)
-
QUOTE:
"as at 08:30:27, Tuesday 30 August, 2016 (NZT)HALFYR: PIL: 600% sales increase for Promisia
PIL
30/08/2016 08:30
HALFYR
PRICE SENSITIVE
REL: 0830 HRS Promisia Integrative Limited
HALFYR: PIL: 600% sales increase for Promisia
Report of the Chairman and Chief Executive
The Chairman and Chief Executive are pleased to report the Half Year Report
for Promisia Integrative Limited and its subsidiaries ("the Group") for the
six month period ended 30 June 2016.
Sales
We are pleased to report healthy sales of $994,098 for Arthrem which is
$850,000, or 600%, more than the sales of $142,000 for the same period in
2015.
According to IRI-AZTEC scan pharmacy data, Arthrem is the fasting growing
brand and product, in dollar terms, for 2016. It also ranks 13th among
brands in dollar terms in pharmacy for New Zealand.
Australia
The company is making good progress towards the launch of Arthrem in
Australia. Arthrem is now manufactured in a Therapeutic Goods of Australia
(TGA) compliant facility with Good Manufacturing Practice certification.
This is an important step, and a prerequisite, to becoming a listed
complementary medicine in Australia. The listing will allow Arthrem to make
stronger evidence-based therapeutic claims in its advertising. Current
legislation prevents these claims being made in New Zealand.
United States of America
Sales in the US continue to grow. Cash spend in the US is being managed
carefully by testing different digital marketing models and using real time
measurement of their effectiveness.
Arthritis supplement for dogs
The major challenge for developing an arthritis supplement product for dogs
using the Group's unique plant extract has been masking the distinctive
pungent smell and bitter taste. Unlike humans, who can swallow a capsule
whole, dogs will smell and chew capsules. Therefore a soft gel capsule is
not an option.
The company's Principal Scientist, Dr Sheena Hunt, has developed a
formulation that masks both the smell and taste of the extract, and is
palatable to dogs. Manufacturing trials are underway.
Financial Results
The $354,000 loss for the Group for the half year, compared to $575,000 for
2015 same period, is slightly below what was expected due to the delayed
expenditure for the launch of Arthrem in Australia and the completion of
development and launch of the arthritis supplement for dogs. Much of this
budgeted expenditure will be incurred in the second half of the year. The
loss includes exchange rate movements, interest expenses, amortisation of the
company's automated marketing website and 50% of known non-cash charges such
as the share option costs.
Research
The focus of the research programme for the first half of the year has been
the development of a palatable formulation for dogs. The company is also
researching other possible therapeutic applications for its extract. A
clinical trial has just started for another product.
Outlook
Promisia will continue to promote Arthrem aggressively in the New Zealand
market. The company is confident that it will exceed its 2016 objective of
capturing at least 3% of the potential New Zealand 305,000 person
osteoarthritis market before the end of the year.
Other priorities for the second half of the year include:
o Listing Arthrem as a complementary medicine in Australia
o Preparation for the launch of Arthrem in Australia in early 2017
o Completion of development and testing of the supplement for dogs
o Preparation of a product launch and marketing campaign for a dog arthritis
treatment in New Zealand and Australia
o Ongoing refinement of the marketing strategy in the US
On behalf of the directors and management we thank shareholders for their
continued support for the company.
End CA:00288096 For:PIL Type:HALFYR Time:2016-08-30 08:30:27"
-
Originally Posted by Left field
Well done holders.....I sense the beginnings of another BLT here!
They are both science / evidence based. So a lot of dosh up front before revenue flows.
Both companies will need a steadily increasing number of repeat customers if they are not to spend too much on attracting new customers.
-
Member
Originally Posted by artemis
They are both science / evidence based. So a lot of dosh up front before revenue flows.
Both companies will need a steadily increasing number of repeat customers if they are not to spend too much on attracting new customers.
Agree to a degree. My casual observation is that PIL are somewhat more conservative and measured in their news than BLT who are keen on at least monthly "news of the day" releases. Both approaches are ok I guess.
-
Quote from above: "...3% of the potential New Zealand 305,000 person osteoarthritis market before the end of the year."
Think i'll just "put this away in the draw" until end of year and they post improved sales.
In the meantime have banged my small holding to a sell at 5c flat. Guess I'll know there's positive action if someone kindly more than doubles my money!
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks